M&A / Deals Roche doubles down on BTK with $2.3bn Nurix deal PharmaphorumRoche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly and Novo face off at ADA 2026 as others seek to compete in obesityNext: Incyte gobbles up Star’s Vega haematology unit in $2bn deal Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
